2) The faculty for this outstanding program were @peters_solange (Chair) π¨π, @HosseinBorghaei πΊπΈ, Natasha Leighl MD π¨π¦, and @dplanchard π«π·. A truly international roster of experts in #oncology!
— @onc_ce (@onc_ce) February 22, 2023
Don't miss prior accredited courses in this space at https://t.co/1GN3yvXUW6.
4) Our understanding and characterization of various subtypes of #LCSM adenocarcinoma continues to expand! This potentially allows for more targeted and safer therapy. Newer markers such as #CEACAM5 are emerging, expanding treatment options ! pic.twitter.com/LRafGQ4mSO
— @onc_ce (@onc_ce) February 22, 2023
6) #Platinum-based chemotherapy has historically been standard #1L for #mNSCLC,
— @onc_ce (@onc_ce) February 22, 2023
BUT
β‘οΈ Responses only in 15β30%
β‘οΈ Relatively short interval until progression.
More recently, #immunotherapy has emerged as a promising alternative βοΈ pic.twitter.com/buWVEKTlXv
8) Immune therapies exploit the host immune system to monitor & destroy cancer cells via the upregulation of key immune checkpoints; at present, #NSCLC immunotherapy mainly refers to immune checkpoint inhibitors (#ICIs). @NCI pic.twitter.com/9IpNpx7JE8
— @onc_ce (@onc_ce) February 22, 2023
10) Currently, programmed death-ligand 1 (#PDL1) expression is the only clinically validated biomarker for selecting patients for tx with an #ICI. pic.twitter.com/07HnKX73XQ
— @onc_ce (@onc_ce) February 22, 2023
12) Letβs discuss treatment #selection! What level of PD-L1 expression is currently preferred for use of single agent immunotherapy?
— @onc_ce (@onc_ce) February 22, 2023
14) Recently, we have seen major progress from targeting #NSCLC beyond chemotx (& PD-L1) w/signal transduction in oncogene addicted NSCLC:
— @onc_ce (@onc_ce) February 22, 2023
πSmall molecule inhibitors, antibodies, ADCs
πEGFR (inc exon20), BRAF, MET, KRAS, ERBB2
πALK, ROS1, NTRK, RET, (NRG1β¦)
15b) Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (#EGFR #TKIs) are the standard of care for patients with EGFR-mutated #LCSM. While EGFR TKIs have initially high response rates, resistance constitute a major challenge to longitudinal tx. pic.twitter.com/AS2B5VP2dX
— @onc_ce (@onc_ce) February 22, 2023
17) Smaller proportions of patients are impacted #mNSCLC driven by #ROS1 fusions, #BRAF mutations, #NTRK fusions, and #RET fusions, where we have witnessed good progress in treatments: pic.twitter.com/HDv6C9NCex
— @onc_ce (@onc_ce) February 22, 2023
19a) We mentioned Anti-#CEACAM5 therapy above . . . CEACAM5 is a #glycoprotein implicated in a variety of oncogenic activities, and was first recognized as a marker for #coloncancer. pic.twitter.com/sWwr6Th5MW
— @onc_ce (@onc_ce) February 22, 2023
19c)
— @onc_ce (@onc_ce) February 22, 2023
π« Most frequent limiting dose toxicity was #keratopathy
Ongoing trials include Ph 2 studies with tusamitamab ravtansine in combination w/ #pembrolizumab (NCT04524689), or #ramucirumab (NCT04394624), and a phase III trial that compares tusamitamab ravtansine w/ #docetaxel
21) Thank you for following this π§΅! You can now claim 0.5hr πCE/#CME by pointing your π±οΈ to https://t.co/S0Oj90c92w. And please follow us here at @onc_ce for more expert education in current topics in #oncology, delivered wholly on Twitter!
— @onc_ce (@onc_ce) February 22, 2023
π@ADesaiMD for editorial support